Literature DB >> 26315607

CDK14 Contributes to Reactive Gliosis via Interaction with Cyclin Y in Rat Model of Spinal Cord Injury.

Chengwei Duan1, Yonghua Liu2, Lu Lu3, Rixin Cai3, Huaqing Xue1, Xingxing Mao4, Chen Chen4, Rong Qian4, Dongmei Zhang5, Aiguo Shen6.   

Abstract

Cyclin-dependent kinases (CDKs) are perceived as the engine that drives cell cycle progression whereas cyclins are considered to be the gears that are changed to aid the transition between cycle phases. CDK14 is a cdc2-related serine/threonine protein kinase and plays an important role in normal cell cycle progression. However, its distribution and function in the central nervous system (CNS) lesion remain unclear. In this study, we mainly investigated the protein expression and cellular localization of CDK14 during spinal cord injury (SCI). Western blot analysis revealed that the expression of CDK14 was gradually increased and reached a peak at 3 days after SCI. The expression of CDK14 was further analyzed by immunohistochemistry. Double immunofluorescence staining showed that CDK14 was co-expressed prominent in astrocytes. Co-localization CDK14/proliferating cell nuclear antigen (PCNA) were detected in glial cells. cyclin Y, which can interact with CDK14, was detected that had same expression trend was consistent with CDK14 Western blot results in SCI. Double-immunofluorescence staining indicated that CDK14 co-expressed with cyclin Y in some cells. Co-immunoprecipitation had been showed that CDK14 could interact with cyclin Y after acute SCI. Taken together, these data suggested that both CDK14 and cyclin Y may play important roles in spinal cord pathophysiology.

Entities:  

Keywords:  CDK14; Cyclin Y; Spinal cord injury

Mesh:

Substances:

Year:  2015        PMID: 26315607     DOI: 10.1007/s12031-015-0639-x

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  31 in total

1.  LDL-receptor-related proteins in Wnt signal transduction.

Authors:  K Tamai; M Semenov; Y Kato; R Spokony; C Liu; Y Katsuyama; F Hess; J P Saint-Jeannet; X He
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

Review 2.  Regeneration beyond the glial scar.

Authors:  Jerry Silver; Jared H Miller
Journal:  Nat Rev Neurosci       Date:  2004-02       Impact factor: 34.870

Review 3.  A monitored contusion model of spinal cord injury in the rat.

Authors:  J A Gruner
Journal:  J Neurotrauma       Date:  1992       Impact factor: 5.269

Review 4.  Role of cell cycle proteins in CNS injury.

Authors:  Kimberly R Byrnes; Alan I Faden
Journal:  Neurochem Res       Date:  2007-04-03       Impact factor: 3.996

5.  Transforming growth factor α transforms astrocytes to a growth-supportive phenotype after spinal cord injury.

Authors:  Robin E White; Meghan Rao; John C Gensel; Dana M McTigue; Brian K Kaspar; Lyn B Jakeman
Journal:  J Neurosci       Date:  2011-10-19       Impact factor: 6.167

6.  A novel cdc2-related protein kinase expressed in the nervous system.

Authors:  M A Lazzaro; P R Albert; J P Julien
Journal:  J Neurochem       Date:  1997-07       Impact factor: 5.372

7.  Role of the cell cycle in the pathobiology of central nervous system trauma.

Authors:  Ibolja Cernak; Bogdan Stoica; Kimberly R Byrnes; Simone Di Giovanni; Alan I Faden
Journal:  Cell Cycle       Date:  2005-09-15       Impact factor: 4.534

8.  Essential protective roles of reactive astrocytes in traumatic brain injury.

Authors:  D J Myer; G G Gurkoff; S M Lee; D A Hovda; M V Sofroniew
Journal:  Brain       Date:  2006-07-05       Impact factor: 13.501

9.  Gene profiling in spinal cord injury shows role of cell cycle in neuronal death.

Authors:  Simone Di Giovanni; Susan M Knoblach; Cinzia Brandoli; Sadia A Aden; Eric P Hoffman; Alan I Faden
Journal:  Ann Neurol       Date:  2003-04       Impact factor: 10.422

Review 10.  Orphan kinases turn eccentric: a new class of cyclin Y-activated, membrane-targeted CDKs.

Authors:  Petra Mikolcevic; Johannes Rainer; Stephan Geley
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

View more
  7 in total

1.  The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.

Authors:  Yunpeng Sun; Pengfei Wang; Wenjun Yang; Yunfeng Shan; Qiyu Zhang; Huanhuan Wu
Journal:  Cancer Biol Ther       Date:  2019-03-27       Impact factor: 4.742

2.  Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells.

Authors:  Lei Zhang; Biwei Ye; Yunfeng Lin; Yi-Dong Li; Jing-Quan Wang; Zhuo Chen; Feng-Feng Ping; Zhe-Sheng Chen
Journal:  Front Pharmacol       Date:  2022-04-01       Impact factor: 5.988

3.  CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells.

Authors:  Lei Zhang; Yidong Li; Chaohua Hu; Yangmin Chen; Zhuo Chen; Zhe-Sheng Chen; Jian-Ye Zhang; Shuo Fang
Journal:  Mol Cancer       Date:  2022-04-22       Impact factor: 41.444

4.  Temporal and Spatial Expression of LGR5 After Acute Spinal Cord Injury in Adult Rats.

Authors:  Xiaoqing Chen; Jie Hao; Ting Fu; Jie Liu; Mingchen Yu; Shuang He; Rong Qian; Feng Zhang
Journal:  Neurochem Res       Date:  2016-06-23       Impact factor: 3.996

5.  Identification of key genes and pathways downstream of the β-catenin-TCF7L1 complex in pancreatic cancer cells using bioinformatics analysis.

Authors:  Yi-Hang Yuan; Jian Zhou; Yan Zhang; Meng-Dan Xu; Jing Wu; Wei Li; Meng-Yao Wu; Dao-Ming Li
Journal:  Oncol Lett       Date:  2019-06-06       Impact factor: 2.967

Review 6.  The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer.

Authors:  Yubing Zhou; Jacson K Shen; Francis J Hornicek; Quancheng Kan; Zhenfeng Duan
Journal:  Oncotarget       Date:  2016-06-28

7.  Lentivirus-mediated silencing of the PTC1 and PTC2 genes promotes recovery from spinal cord injury by activating the Hedgehog signaling pathway in a rat model.

Authors:  Ya-Dong Zhang; Zhong-Sheng Zhu; Dong Zhang; Zhen Zhang; Bin Ma; Shi-Chang Zhao; Feng Xue
Journal:  Exp Mol Med       Date:  2017-12-15       Impact factor: 8.718

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.